Trial Profile

The development of a novel dual-targeting peptide vaccine therapy in patients with resected pancreatic cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OCV C01 (Primary) ; Gemcitabine
Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
25 Jan 2020 Primary endpoint (Disease-free survival) has been met presented at the 2020 Gastrointestinal Cancers Symposium
25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com